【Rakuoilia Pharmaceutical】Addition of New Indications for tegoprazan in South Korea｜July 2026

Performance Overview

Rakuoilia Pharmaceutical announced the addition of indications for the gastric acid suppressant tegoprazan in South Korea via its licensing partner HK Innoen. The newly approved indication is for the prevention of digestive ulcers related to NSAID use, bringing the total indications in the South Korean market to six. As of April 2026, sales in South Korea reached approximately 110 billion yen, maintaining the market share at No.1. The company has expressed its intention to continue expanding its presence in the South Korean market and to enhance long-term corporate value.

Future Outlook and Investor Impact

The addition of indications in South Korea is expected to expand tegoprazan’s market and strengthen its revenue base. Rakuoilia Pharmaceutical plans to further reinforce its collaboration with HK Innoen, promote new indications, and enhance sales. This is anticipated to lead to long-term revenue growth and increase corporate value, making it an attractive growth factor for investors.